1. Winslow BT, Vandal C, Dang L. Fibromyalgia: diagnosis and management. Am Fam Physician. 2023;107(2):137-144.

2. Macfarlane GJ, Kronisch C, Dean LE, et al. EULAR revised recommendations for the management of fibromyalgia. Ann Rheum Dis. 2017;76(2):318-328.

3. Wessely S, Hotopf M. Is fibromyalgia a distinct clinical entity? Historical and epidemiological evidence. Baillieres Best Pract Res Clin Rheumatol. 1999;13(3):427-436.

4. Griffing GT. Fibromyalgia is not a rheumatologic disease anymore. Medscape J Med. 2008;10(2):47.

5. Nijs J, George SZ, Clauw DJ, et al. Central sensitization in chronic pain conditions: latest discoveries and their potential for precision medicine. Lancet Rheumatol. 2021;3:e383-e392.

6. Agarwal A, Emary PC, Gallo L, et al. Physicians' knowledge, attitudes, and practices regarding fibromyalgia: a systematic review and meta-analysis of cross-sectional studies. Medicine (Baltimore). 2024;103(31):e39109.

7. Mease P. Fibromyalgia syndrome: review of clinical presentation, pathogenesis, outcome measures, and treatment. J Rheumatol Suppl. 2005;75:6-21.

8. Wolfe F, Smythe HA, Yunus MB, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum. 1990;33(2):160-172.

9. Jones J, Rutledge DN, Jones KD, Matallana L, Rooks DS. Self-assessed physical function levels of women with fibromyalgia: a national survey. Wom Health Iss. 2008;18(5):406-412.

10. Navarro RP. Contemporary management strategies for fibromyalgia. Am J Manag Care. 2009;15(7 Suppl):S197-S218.

11. D'Onghia M, Ciaffi J, Ruscitti P, et al. The economic burden of fibromyalgia: a systematic literature review. Semin Arthritis Rheum. 2022;56:152060.

12. Berger A, Sadosky A, Dukes EM, Edelsberg J, Zlateva G, Oster G. Patterns of healthcare utilization and cost in patients with newly diagnosed fibromyalgia. Am J Manage Care. 2010;16(5 Suppl):S126-S137.

13. Heidari F, Afshari M, Moosazadeh M. Prevalence of fibromyalgia in general population and patients: a systematic review and meta-analysis. Rheumatol Int. 2017;37(9):1527-1539.

14. Henley P, Martins T, Zamani R. Assessing ethnic minority representation in fibromyalgia clinical trials: a systematic review of recruitment demographics. Int J Environ Res Public Health. 2023;20(24):7185.

15. Jacobs M, Crall E, Menzies V. Fibromyalgia syndrome among men and women: symptom identification, diagnosis, and concurrence in a nationally representative sample. Open Rheumat J. 2024;18:e18743129356140.

16. Staines DR. Is fibromyalgia an autoimmune disorder of endogenous vasoactive neuropeptides? Med Hypotheses. 2004;62(5):665-669.

17. Williams DA, Schilling S. Advances in the assessment of fibromyalgia. Rheum Dis Clin North Am. 2009;35(2):339-357.

18. Moldofsky H, Scarisbrick P, England R, Smythe H. Musculoskeletal symptoms and non-REM sleep disturbance in patients with ''fibrositis syndrome'' and healthy subjects. Psychosom Med. 1975;37(4):341-351.

19. Ablin JN. Fibromyalgia: are you a genetic/environmental disease? Pain Rep. 2025;10(3):e1256.

20. Bennett RM, Jones J, Turk DC, Russell IJ, Matallana L. An internet survey of 2,596 people with fibromyalgia. BMC Musculoskelet Disord. 2007;8:27.

21. Motley CP, Maxwell ML. Fibromyalgia: helping your patient while maintaining your sanity. Prim Care. 2010;37(4):743-755.

22. Weir PT, Harlan GA, Nkoy FL, et al. The incidence of fibromyalgia and its associated comorbidities: a population-based retrospective cohort study based on International Classification of Diseases, 9th Revision codes. J Clin Rheumatol. 2006;12(3):124-128.

23. Buskila D, Sarzi-Puttini P. Fibromyalgia and autoimmune diseases: the pain behind autoimmunity. Isr Med Assoc J. 2008;10(1):77-78.

24. Bazzichi L, Rossi A, Zirafa C, et al. Thyroid autoimmunity may represent a predisposition for the development of fibromyalgia? Rheumatol Int. 2012;32(2):335-341.

25. Wolfe F, Clauw DJ, Fitzcharles MA, et al. The American College of Rheumatology 2016 revisions to the 2010/2011 fibromyalgia diagnostic criteria. Semin Arthritis Rheum. 2016;46(3):319-329.

26. Arthritis Foundation. Fibro Fog. Available at https://www.arthritis.org/diseases/more-about/fibro-fog. Last accessed August 15, 2026.

27. National Fibromyalgia Association. Cognitive Function & Fibromyalgia (Fibro Fog). Available at https://www.fmaware.org/cognitive-function-fibromyagia-fibro-fog. Last accessed August 15, 2026.

28. Ibraheem W, Mckenzie S, Wilcox-Omubo V, et al. Pathophysiology and clinical implications of cognitive dysfunction in fibromyalgia. Cureus. 2021;13(10):e19123.

29. Glass JM. Review of cognitive dysfunction in fibromyalgia: a convergence on working memory and attentional control impairments. Rheum Dis Clin North Am. 2009;35(2):299-311.

30. Arnold, LM, Bennett RM, Crofford, LJ, et al. AAPT Diagnostic Criteria for Fibromyalgia. J Pain. 2019;20(6):611-628.

31. Kleykamp BA, Ferguson MC, McNicol E, et al. The prevalence of psychiatric and chronic pain comorbidities in fibromyalgia: an ACTTION systematic review. Semin Arthritis Rheum. 2021;51(1):166-174.

32. Perrot S, Bouhassira D, Fermanian J, Cercle d'Etude de la Douleur en Rhumatologie. Development and validation of the Fibromyalgia Rapid Screening Tool (FiRST). Pain. 2010;150(2):250-256.

33. Merriweather E, Rake B, Zimmerman M, et al. (115) Validity and reliability of the Patient-Reported Outcomes Measurement Information System (PROMIS) for pain interference and quality of life in women with fibromyalgia. J Pain. 2015;16(4):10.1016.

34. Mease PJ, Arnold LM, Crofford LJ, et al. Identifying the clinical domains of fibromyalgia: contributions from clinician and patient Delphi exercises. Arthritis Rheum. 2008;59(7):952-960.

35. Arnold LM. The pathophysiology, diagnosis and treatment of fibromyalgia. Psychiatr Clin North Am. 2010;33(2):375-408.

36. Wolfe F, Michaud K, Li T, Katz RS. Chronic conditions and health problems in rheumatic diseases: comparisons with rheumatoid arthritis, noninflammatory rheumatic disorders, systemic lupus erythematosus, and fibromyalgia. J Rheumatol. 2010;37(2):305-315.

37. Straub L, Mounsey A. FM/a blood test for diagnosis of fibromyalgia. Am Fam Physician. 2021;103(9):566-567.

38. Buckhardt C, Goldenberg D, Crofford L, et al. Guideline for the Management of Fibromyalgia Syndrome Pain in Adults and Children. Glenview, IL: American Pain Society; 2005.

39. U.S. Census Bureau. Selected Social Characteristics in the United States: 2024. Available at https://data.census.gov/table/ACSDP1Y2024.DP02. Last accessed August 1, 2026.

40. Karliner LS, Napoles-Springer AM, Schillinger D, Bibbins-Domingo K, Pérez-Stable EJ. Identification of limited English proficient patients in clinical care. J Gen Intern Med. 2008;23(10):1555-1560.

41. Flores G. Language barriers to health care in the United States. N Engl J Med. 2006;355(3):229-231.

42. Flores G. The impact of medical interpreter services on the quality of health care: a systematic review. Med Care Res Rev. 2005;62(3): 255-299.

43. Karliner LS, Jacobs EA, Chen AH, Mutha S. Do professional interpreters improve clinical care for patients with limited English proficiency? A systematic review of the literature. Health Serv Res. 2007;42(2):727-754.

44. Rooks DS, Gautam S, Romeling M, et al. Group exercise, education, and combination self-management in women with fibromyalgia: a randomized trial. Arch Intern Med. 2007;167(20):2192-2200.

45. Jones KD, Liptan GL. Exercise interventions in fibromyalgia: clinical applications from the evidence. Rheum Dis Clin North Am. 2009;35(2):373-391.

46. Häuser W, Klose P, Langhorst J, et al. Efficacy of different types of aerobic exercise in fibromyalgia syndrome: a systematic review and meta-analysis of randomised controlled trials. Arthritis Res Ther. 2010;12(3):R79.

47. Busch AJ, Barber KAR, Overend TJ, Peloso PM, Schachter CL. Exercise for treating fibromyalgia syndrome. Cochrane Database Syst Rev. 2008(4):CD003786.

48. Busch AJ, Webber SC, Richards RS, et al. Resistance exercise training for fibromyalgia. Cochrane Database Syst Rev. 2013;12:CD010884.

49. Wang C, Schmid CH, Fielding WF, et al. Effect of tai chi versus aerobic exercise for fibromyalgia: comparative effectiveness randomized trial. BMJ. 2018;360:k851.

50. Hassett AL, Gevirtz RN. Nonpharmacologic treatment for fibromyalgia: patient education, cognitive-behavioral therapy, relaxation techniques, and complementary and alternative medicine. Rheum Dis Clin North Am. 2009;35(2):393-407.

51. Glombiewski JA, Sawyer AT, Gutermann J, Koenig K, Rief W, Hofmann SG. Psychological treatments for fibromyalgia: a meta-analysis. Pain. 2010;151(2):280-295.

52. Lauche R, Cramer H, Dobos G, Langhorst J, Schmidt S. A systematic review and meta-analysis of mindfulness-based stress reduction for the fibromyalgia syndrome. J Psychosom Res. 2013;75(6):500-510.

53. Shaver JL, Wilbur J, Lee H, Robinson FP, Wang E. Self-reported medication and herb/supplement use by women with and without fibromyalgia. J Womens Health. 2009;18(5):709-716.

54. Wahner-Roedler DL, Elkin PL, Vincent A, et al. Use of complementary and alternative medical therapies by patients referred to a fibromyalgia treatment program at a tertiary care center. Mayo Clin Proc. 2005;80(1):55-60.

55. Deare JC, Zheng Z, Xue CC, et al. Acupuncture for treating fibromyalgia. Cochrane Database Syst Rev. 2013;5:CD007070.

56. Li Y, Wang F, Feng C, Yang X, Sun Y. Massage therapy for fibromyalgia: a systematic review and meta-analysis of randomized controlled trials. PLoS One. 2014;9(2):e89304.

57. Lauche R, Cramer H, Hauser W, Dobos G, Langhorst J. A systematic review and meta-analysis of qigong for the fibromyalgia syndrome. Evid Based Complement Alternat Med. 2013;2013:635182.

58. LexiDrug. Available at https://online.lexi.com. Last accessed August 15, 2026.

59. Hujjat SFZ, Zahra SH, Abbas T, Kalam H. Tonmya (cyclobenzaprine hydrochloride sublingual tablets): first FDA-approved therapy for fibromyalgia in over 15 years. Ann Med Surg. 2025;87(12):7868-7869.

60. Kia S, Choy E. Update on Treatment Guideline in Fibromyalgia Syndrome with focus on pharmacology. Biomedicines. 2017;5(2):20.

61. Mease PJ, Russell IJ, Kajdasz DK, et al. Long-term safety, tolerability, and efficacy of duloxetine in the treatment of fibromyalgia. Semin Arthritis Rheum. 2010;39(6):454-464.

62. Russell IJ, Mease PJ, Smith TR, et al. Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial. Pain. 2008;136(3):432-444.

63. Lunn MP, Hughes RA, Wiffen PJ. Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia. Cochrane Database Syst Rev. 2014;1:CD007115.

64. Clauw DJ, Mease P, Palmer RH, Gendreau RM, Wang Y. Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial. Clin Ther. 2008;30(11):1988-2004.

65. Mease PJ, Clauw DJ, Gendreau RM, et al. The efficacy and safety of milnacipran for treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial. J Rheumatol. 2009;36(2):398-409.

66. Mease PJ, Choy EH. Pharmacotherapy of fibromyalgia. Rheum Dis Clin North Am. 2009;35(2):359-372.

67. Wiffen PJ, Derry S, Moore RA, et al. Antiepileptic drugs for neuropathic pain and fibromyalgia: an overview of Cochrane reviews. Cochrane Database Syst Rev. 2013;11:CD010567.

68. Crofford LJ, Rowbotham MC, Mease PJ, et al. Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2005;52(4):1264-1273.

69. Tofferi JK, Jackson JL, O'Malley PG. Treatment of fibromyalgia with cyclobenzaprine: a meta-analysis. Arthritis Rheum. 2004;51(1):9-13.

1. Macfarlane GJ, Kronisch C, Dean LE, et al. EULAR revised recommendations for the management of fibromyalgia. Ann Rheum Dis. 2017;76(2):318-328. Available at https://ard.bmj.com/content/76/2/318. Last accessed August 27, 2026.